Literature DB >> 26463131

Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction.

Rajinder Singh1, Arvinder Sran1, David C Carroll1, Jianing Huang1, Lyuben Tsvetkov1, Xiulan Zhou1, Julie Sheung1, John McLaughlin1, Sarkiz D Issakani1, Donald G Payan1, Simon J Shaw2.   

Abstract

Structure-activity relationships have been developed around 5-bromo-8-toluylsulfonamidoquinoline 1 a hit compound in an assay for the interaction of the E3 ligase Skp2 with Cks1, part of the SCF ligase complex. Disruption of this protein-protein interaction results in higher levels of CDK inhibitor p27, which can act as a tumor suppressor. The results of the SAR developed highlight the relationship between the sulfonamide and quinoline nitrogen, while also suggesting that an aryl substituent at the 5-position of the quinoline ring contributes to the potency in the interaction assay. Compounds showing potency in the interaction assay result in greater levels of p27 and have been shown to inhibit cell growth of two p27 sensitive tumor cell lines.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-cancer; E3 ubiquitin ligases; Protein–protein interactions; Structure–activity relationships; p27

Mesh:

Substances:

Year:  2015        PMID: 26463131     DOI: 10.1016/j.bmcl.2015.09.067

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells.

Authors:  Jingna Su; Lixia Wang; Xuyuan Yin; Zhe Zhao; Yingying Hou; Xiantao Ye; Xiuxia Zhou; Zhiwei Wang
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 2.  Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.

Authors:  Pranav Gupta; Hongling Zhao; Bang Hoang; Edward L Schwartz
Journal:  Br J Cancer       Date:  2022-06-25       Impact factor: 9.075

Review 3.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 4.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.

Authors:  Xu Ran; Jason E Gestwicki
Journal:  Curr Opin Chem Biol       Date:  2018-06-13       Impact factor: 8.822

5.  Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.

Authors:  Hongling Zhao; Niloy J Iqbal; Vineeth Sukrithan; Cari Nicholas; Yingjiao Xue; Cindy Yu; Joseph Locker; Juntao Zou; Edward L Schwartz; Liang Zhu
Journal:  Cancer Res       Date:  2020-04-07       Impact factor: 12.701

Review 6.  Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.

Authors:  Lea Lough; Dan Sherman; Eric Ni; Lauren M Young; Bing Hao; Timothy Cardozo
Journal:  Medchemcomm       Date:  2018-06-11       Impact factor: 3.597

7.  A general method for the metal-free, regioselective, remote C-H halogenation of 8-substituted quinolines.

Authors:  Damoder Reddy Motati; Dilipkumar Uredi; E Blake Watkins
Journal:  Chem Sci       Date:  2018-01-05       Impact factor: 9.825

Review 8.  F-Box Proteins and Cancer.

Authors:  Kanae Yumimoto; Yuhei Yamauchi; Keiichi I Nakayama
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 9.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

10.  miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.

Authors:  Sara E Meyer; David E Muench; Andrew M Rogers; Tess J Newkold; Emily Orr; Eric O'Brien; John P Perentesis; John G Doench; Ashish Lal; Patrick J Morris; Craig J Thomas; Judy Lieberman; Edwina McGlinn; Bruce J Aronow; Nathan Salomonis; H Leighton Grimes
Journal:  J Exp Med       Date:  2018-07-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.